Spike Protein News and Research

RSS

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.

16 Apr 2021

Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein

A new study posted to the bioRxiv preprint server focuses on a novel formulation of magnetization or saturation transfer. This method is developed by amalgamating theoretical and computational approaches based on a Bayesian deconvolution algorithm, which helps obtain data more accurately and determine the ligand-protein interaction.

16 Apr 2021

Modeling study suggests how different SARS-CoV-2 mutations prevent antibody binding

This suggests a cocktail of antibodies will work better at neutralizing the virus than a single antibody alone. In a study published in the bioRxiv* preprint server, researchers report the structure of binding complexes of the different classes of antibodies to the spike RBD using computational modeling, which may also help explain how the virus generates escape mutations.

16 Apr 2021

More SARS-CoV-2 variants have emerged from immunocompromised hosts, shows research

A number of SARS-CoV-2 variants have emerged from immunocompromised hosts, research has identified. It is thought that variants of concern - including B.1.1.7, a variant first identified in Kent - were a result of long-term infection in people with a weakened immune system.

16 Apr 2021

Single dose of Oxford–AstraZeneca COVID vaccine shown to be more immunogenic than natural infection

By investigating antibody and T cell responses to a single dose of the Oxford–AstraZeneca COVID-19 vaccine, researchers from Sri Lanka and the United Kingdom have found that more than 90% of vaccinated individuals produced an adequate amount of antibodies after receiving only one dose of the vaccine – irrespective of their age and gender.

16 Apr 2021

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Researchers in the United States have demonstrated the efficacy of the vaccine INO-4800 against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Apr 2021

Researchers develop “Nano-Glue” with therapeutic potential against SARS-CoV-2

In a recent study, researchers target the electropositive receptor-binding domain (RBD) on the SARS-CoV-2 spike protein with the abundant β-sheet structure as a novel COVID-19 therapeutic drug design.

15 Apr 2021

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.

14 Apr 2021

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

14 Apr 2021

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Researchers in the United States have predicted the binding epitopes of uncharacterized neutralizing antibodies that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

14 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

The study, published in The Lancet, demonstrates that there is no evidence of a link between severe illness and death and lineage when comparing the B.1.1.7 lineage and other variants.

14 Apr 2021

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

The spike protein is the main part of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the infection. It consists of two subunits S1 and S2. Upon entry of the virus into the human body, the S1 subunit helps the virus bind to the angiotensin-converting enzyme 2 (ACE2) receptors on host cells.

13 Apr 2021

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Researchers in the United States have identified 95 high-frequency mutations in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that threaten to compromise the efficacy of current and future vaccines and antibody therapies for coronavirus disease 2019 (COVID-19).

13 Apr 2021

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently neutralize variants of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Apr 2021

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

In a recent bioRxiv* preprint, the large team of researchers evaluated a SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model. This study addresses the need for a next-generation, efficacious vaccine with an increased pan-SARS breadth of coverage.

13 Apr 2021

Spike Protein News and Research

Curcumin nanosystems could be powerful COVID-19 therapeutics

Bristol-based new biotech company is developing ground-breaking treatments for Covid-19

Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein

Modeling study suggests how different SARS-CoV-2 mutations prevent antibody binding

More SARS-CoV-2 variants have emerged from immunocompromised hosts, shows research

Single dose of Oxford–AstraZeneca COVID vaccine shown to be more immunogenic than natural infection

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Researchers develop “Nano-Glue” with therapeutic potential against SARS-CoV-2

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

Researchers develop model for SARS-CoV-2 fusion intermediate that helps membrane fusion

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News